Weight gain and integrase inhibitors
AR Eckard, GA McComsey - Current opinion in infectious diseases, 2020 - journals.lww.com
Although INSTI-based regimens are highly efficacious for viral suppression, they appear to
cause more weight gain and treatment emergent obesity than non-INSTI-based regimens …
cause more weight gain and treatment emergent obesity than non-INSTI-based regimens …
[HTML][HTML] Cabotegravir for HIV prevention in cisgender men and transgender women
RJ Landovitz, D Donnell, ME Clement… - … England Journal of …, 2021 - Mass Medical Soc
Background Safe and effective long-acting injectable agents for preexposure prophylaxis
(PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options …
(PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options …
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial …
WDF Venter, S Sokhela, B Simmons, M Moorhouse… - The lancet HIV, 2020 - thelancet.com
Background ADVANCE compared the efficacy and safety of two antiretroviral first-line
combinations (dolutegravir combined with emtricitabine and either tenofovir disoproxil …
combinations (dolutegravir combined with emtricitabine and either tenofovir disoproxil …
Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors …
K Bourgi, CA Jenkins, PF Rebeiro… - Journal of the …, 2020 - Wiley Online Library
Introduction Weight gain following antiretroviral therapy (ART) initiation is common,
potentially predisposing some persons with HIV (PWH) to cardio‐metabolic disease. We …
potentially predisposing some persons with HIV (PWH) to cardio‐metabolic disease. We …
HIV and antiretroviral therapy-related fat alterations
Early in the HIV epidemic, lipodystrophy, characterized by subcutaneous fat loss
(lipoatrophy), with or without central fat accumulation (lipohypertrophy), was recognized as a …
(lipoatrophy), with or without central fat accumulation (lipohypertrophy), was recognized as a …
Risk factors for weight gain following switch to integrase inhibitor–based antiretroviral therapy
JE Lake, K Wu, SH Bares, P Debroy… - Clinical Infectious …, 2020 - academic.oup.com
Background Treatment initiation with integrase strand transfer inhibitors (INSTIs) has been
associated with excess weight gain. Whether similar gains are seen after switch to INSTIs …
associated with excess weight gain. Whether similar gains are seen after switch to INSTIs …
HIV-1 integrase inhibitors: a comparative review of efficacy and safety
KK Scarsi, JP Havens, AT Podany, SN Avedissian… - Drugs, 2020 - Springer
The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …
Weight gain before and after switch from TDF to TAF in a US cohort study
PWG Mallon, L Brunet, RK Hsu, JS Fusco… - African Journal of …, 2021 - journals.lww.com
Introduction: Although weight gain has been reported with the use of integrase strand
transfer inhibitors (InSTI), concurrent use of tenofovir alafenamide (TAF) has been implicated …
transfer inhibitors (InSTI), concurrent use of tenofovir alafenamide (TAF) has been implicated …
Obesity and weight gain in persons with HIV
SS Bailin, CL Gabriel, CN Wanjalla… - Current HIV/AIDS Reports, 2020 - Springer
Abstract Purpose of Review The proportion of overweight and obese persons with HIV
(PWH) has increased since the introduction of antiretroviral therapy (ART). We aim to …
(PWH) has increased since the introduction of antiretroviral therapy (ART). We aim to …